Next Century Growth Investors’s Accelerate Diagnostics AXDX Stock Holding History

Next Century Growth Investors’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-18,017	Closed	-$3.35M	–	129
2019 Q3	$3.35M	Sell	18,017 -4,547	-20%	-$879K	0.54%	60
2019 Q2	$5.16M	Sell	22,564 -302	-1%	-$59.1K	0.64%	47
2019 Q1	$4.81M	Sell	22,866 -12,287	-35%	-$2.3M	0.64%	58
2018 Q4	$4.04M	Sell	35,153 -25,554	-42%	-$3.79M	0.58%	71
2018 Q3	$13.9M	Sell	60,707 -504	-0.8%	-$111K	1.62%	12
2018 Q2	$13.6M	Buy	61,211 +8,037	+15%	+$1.8M	1.74%	12
2018 Q1	$12.2M	Sell	53,174 -12,828	-19%	-$3.37M	1.62%	21
2017 Q4	$17.3M	Buy	66,002 +15,439	+31%	+$3.62M	2.15%	9
2017 Q3	$11.4M	Sell	50,563 -1,853	-4%	-$455K	1.36%	25
2017 Q2	$14.3M	Buy	52,416 +18,675	+55%	+$5.06M	1.37%	26
2017 Q1	$8.16M	Sell	33,741 -13,035	-28%	-$2.98M	0.69%	58
2016 Q4	$9.71M	Buy	46,776 +2,987	+7%	+$709K	0.59%	59
2016 Q3	$11.9M	Buy	+43,789	New	+$9.69M	0.55%	64

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Next Century Growth Investors's AXDX Position: Q4 2019 in Review

Next Century Growth Investors sold out of Accelerate Diagnostics (AXDX) in Q4 2019, closing a stake of 18,017 shares — an estimated $3.35M sold.

Next Century Growth Investors first reported a position in AXDX in Q3 2016 and held it in 13 quarters. The position peaked at $17.3M in Q4 2017. 109 funds tracked by Wall St. Rank hold AXDX as of Q4 2019.

Next Century Growth Investors reported no remaining Accelerate Diagnostics position as of Q4 2019 after selling out during the quarter.
Next Century Growth Investors sold 18,017 Accelerate Diagnostics shares in Q4 2019, an estimated $3.35M.
Next Century Growth Investors first reported a position in Accelerate Diagnostics in Q3 2016 and held it in 13 quarters.
Next Century Growth Investors's Accelerate Diagnostics position peaked at $17.3M in Q4 2017.
109 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2019.

Based on Next Century Growth Investors's 13F filing for Q4 2019, filed 14 Feb 2020.